A Phase 1 interventional study of Cabotegravir Tablets and Rilpivirine Tablets in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 33rd largest by enrollment, is one of 6 that started in 2020, is one of 10 in phase 1, and was the 19th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 197th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2020, is one of 83 in phase 1, and was the 209th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is a phase 1, open label study in healthy participants to assess the pharmacokinetics of cabotegravir and rilpivirine in plasma following the administration of a single 600 milligram (mg) and a 900 mg intramuscular (IM) injection respectively, to separate vastus lateralis muscles on each leg. Cabotegravir is an integrase inhibitor being developed in combination with rilpivirine, a non-nucleoside reverse transcriptase inhibitor, for the treatment of human immunodeficiency virus (HIV). The objective is to evaluate pharmacokinetics, tolerability, and safety of cabotegravir long acting plus rilpivirine long acting administered concomitantly as two separate IM injections in the vastus lateralis muscle of adult healthy participants. The screening phase will be of 30 days, oral lead-in (OLI) phase of 28 days, there will be washout period of 10-14 days, followed by an injection phase and follow-up period will be up to 52-weeks. Approximately 15 adult healthy participants will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered cabotegravir at a dose of 30 mg plus rilpivirine dose of 25 mg once daily with meal on Day 1 to Day 28 in OLI phase. There will be 10 to 14 days wash out period after OLI. This will be followed by an injection phase, wherein participants will receive 600 mg cabotegravir long acting given as one 3 milliliter (mL) IM injection plus 900 mg rilpivirine long acting given as one 3 mL IM injection on Day 1.
Drug: Cabotegravir Tablets · Drug: Rilpivirine Tablets · Drug: Cabotegravir extended release suspension for injection (long-acting) · Drug: Rilpivirine extended release suspension for injection (long-acting)
Cabotegravir tablets will be white to almost white oval shaped film coated tablets with a unit dose of 30 mg and will be administered orally.
Rilpivirine tablets will be off-white, round, biconvex film coated tablets with a unit dose of 25 mg and will be administered orally.
Cabotegravir long-acting will be a sterile white to slightly pink suspension containing 200 mg per mL of GSK1265744 as free acid for administration by intramuscular injection.
Rilpivirine long-acting will be a sterile white suspension containing 300 mg per mL of rilpivirine as the free base for administration by intramuscular injection.
Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Cmax of Rilpivirine (RPV) Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of RPV.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Time of Cmax (Tmax) of CAB Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of CAB.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Tmax of RPV Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of RPV.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of CAB.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
AUC(0-t) of RPV Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of RPV.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of CAB Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of CAB.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
AUC(0-infinity) of RPV Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of RPV.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Apparent Terminal Phase Half-life (t1/2) of CAB Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of CAB.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
t1/2 of RPV Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of RPV.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Geometric Mean of Absorption Rate Constant (KALA) of CAB Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of CAB.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Geometric Mean of Absorption Rate Constant (KALA) of RPV Following Single IM Injection
Blood samples were collected at indicated time points for PK analysis of RPV.
Time frame: Day 1 (pre-dose, 1 hour, 2 hours) and one post-dose sample on day 2, day 4, day 5, day 8, day 10, day 15, day 17, day 22, day 28, week 8, week 12, week 24, week 36 and week 52
Number of Participants With Liver Related Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to 56 weeks
Number of Participants With Liver Related Abnormalities
Blood samples were collected to assess abnormalities related to liver.
Time frame: Up to 56 weeks
| Milestone | Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | Injection Phase - CAB 600mg + RPV 900mg | Follow-up Phase - CAB 600mg + RPV 900mg |
|---|---|---|---|
| Started | 15 | 0 | 0 |
| Completed | 14 | 0 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Milestone | Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | Injection Phase - CAB 600mg + RPV 900mg | Follow-up Phase - CAB 600mg + RPV 900mg |
|---|---|---|---|
| Started | 0 | 14 | 0 |
| Completed | 0 | 14 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | Injection Phase - CAB 600mg + RPV 900mg | Follow-up Phase - CAB 600mg + RPV 900mg |
|---|---|---|---|
| Started | 0 | 0 | 14 |
| Completed | 0 | 0 | 14 |
| Not completed | 0 | 0 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB.
| Microgram per milliliter (ug/mL) | IM CAB 600 mg |
|---|---|
| Maximum Observed Concentration (Cmax) of Cabotegravir (CAB) Following Single IM Injection | 3.38 ± 66 |
Blood samples were collected at indicated time points for PK analysis of RPV.
| nanogram per milliliter (ng/mL) | IM RPV 900mg |
|---|---|
| Cmax of Rilpivirine (RPV) Following Single IM Injection | 93.5 ± 37.7 |
Blood samples were collected at indicated time points for PK analysis of CAB.
| Hour | IM CAB 600 mg |
|---|---|
| Time of Cmax (Tmax) of CAB Following Single IM Injection | 167 (166 to 1317) |
Blood samples were collected at indicated time points for PK analysis of RPV.
| Hour | IM RPV 900mg |
|---|---|
| Tmax of RPV Following Single IM Injection | 131 (70.1 to 647) |
Blood samples were collected at indicated time points for PK analysis of CAB.
| Hour*microgram per milliliter (h*ug/mL) | IM CAB 600 mg |
|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time (AUC[0-t]) of CAB Following Single IM Injection | 3612 ± 23 |
Blood samples were collected at indicated time points for PK analysis of RPV.
| h*ng/mL | IM RPV 900mg |
|---|---|
| AUC(0-t) of RPV Following Single IM Injection | 143891 ± 33 |
Blood samples were collected at indicated time points for PK analysis of CAB.
| h*ug/mL | IM CAB 600 mg |
|---|---|
| AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) of CAB Following Single IM Injection | 3948 ± 21.5 |
Blood samples were collected at indicated time points for PK analysis of RPV.
| h*ng/mL | IM RPV 900mg |
|---|---|
| AUC(0-infinity) of RPV Following Single IM Injection | 171953 ± 31.1 |
Blood samples were collected at indicated time points for PK analysis of CAB.
| Days | IM CAB 600 mg |
|---|---|
| Apparent Terminal Phase Half-life (t1/2) of CAB Following Single IM Injection | 21.4 ± 79.3 |
Blood samples were collected at indicated time points for PK analysis of RPV.
| Days | IM RPV 900mg |
|---|---|
| t1/2 of RPV Following Single IM Injection | 137 ± 26.6 |
Blood samples were collected at indicated time points for PK analysis of CAB.
| Per hour (/h) | IM CAB 600 mg |
|---|---|
| Geometric Mean of Absorption Rate Constant (KALA) of CAB Following Single IM Injection | 0.00135 ± 79.3 |
Blood samples were collected at indicated time points for PK analysis of RPV.
| Per hour (/h) | IM RPV 900mg |
|---|---|
| Geometric Mean of Absorption Rate Constant (KALA) of RPV Following Single IM Injection | 0.000211 ± 26.6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | Injection Phase - CAB 600mg + RPV 900mg | Follow-up Phase - CAB 600mg + RPV 900mg |
|---|---|---|---|
| Number of Participants With Liver Related Adverse Events (AEs) | 0 | 0 | 0 |
Blood samples were collected to assess abnormalities related to liver.
| Participants | Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | Injection Phase - CAB 600mg + RPV 900mg | Follow-up Phase - CAB 600mg + RPV 900mg |
|---|---|---|---|
| Number of Participants With Liver Related Abnormalities | 0 | 0 | 0 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 56 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Injection Phase - CAB 600mg + RPV 900mg | 0/14 (0%) | 0/14 (0%) | 14/14 (100%) |
| Follow-up Phase - CAB 600mg + RPV 900mg | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Event | Oral lead-in Phase - Cabotegravir (CAB) 30 Microgram (mg) + Rilpivirine (RPV) 25mg | Injection Phase - CAB 600mg + RPV 900mg | Follow-up Phase - CAB 600mg + RPV 900mg |
|---|---|---|---|
| Injection site painGeneral disorders | 0/15 | 14/14 | 0/14 |
| Injection site erythemaGeneral disorders | 0/15 | 8/14 | 0/14 |
| Injection site indurationGeneral disorders | 0/15 | 7/14 | 0/14 |
| Injection site swellingGeneral disorders | 0/15 | 6/14 | 0/14 |
| Injection site bruisingGeneral disorders | 0/15 | 4/14 | 0/14 |
| ChillsGeneral disorders | 0/15 | 3/14 | 0/14 |
| Injection site warmthGeneral disorders | 0/15 | 3/14 | 0/14 |
| Injection site pruritusGeneral disorders | 0/15 | 2/14 | 0/14 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/15 | 2/14 | 0/14 |
| BlepharitisEye disorders | 0/15 | 1/14 | 0/14 |
All enrolled population included participants who signed the informed consent form and received at least 1 dose of study drug.
| Age, Continuous(YEARS) | All Enrolled Participants |
|---|---|
| Mean | 34.3 ± 7.72 |
| Sex: Female, Male(Participants) | All Enrolled Participants |
|---|---|
| Female | 6 |
| Male | 9 |
| Race/Ethnicity, Customized(Participants) | All Enrolled Participants |
|---|---|
| Asian | 1 |
| Black or African American | 7 |
| White | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2020 to primary completion in Dec 2021, 15 months.
Results were first posted in Apr 2024, 2 years 3 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 15 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabotegravir · Rilpivirine